Vistagen Therapeutics, Inc. (VTGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD.

Revenue Annual

-800K 0 800K 1.6M 2.4M FY11: 2.1M FY12: 1.3M FY13: 200.4K FY16: 0 FY17: 1.2M FY18: 0 FY20: 0 FY21: 1.1M FY22: 1.1M FY23: -227K FY24: 1.1M FY25: 486K FY26: 1.3M FY11 FY13 FY17 FY20 FY22 FY24 FY26

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-75M -50M -25M 0 25M 50M 75M FY11: -6.6M FY12: -9M FY13: -6.8M FY14: -5M FY15: -6.8M FY16: -17.9M FY17: -10.2M FY18: -14.2M FY19: -24.6M FY20: -20.8M FY21: -17.9M FY22: -47.8M FY23: -59.3M FY24: -33M FY25: -56M FY26: -72.1M FY12 FY14 FY16 FY18 FY20 FY22 FY24 FY26

Net Income Annual

-75M -50M -25M 0 25M 50M 75M FY00: -700K FY01: -1.8M FY02: -2.1M FY03: -502.6K FY04: -8.8M FY05: -1.1M FY06: -1.8M FY07: -2M FY08: -5.4M FY09: -4.7M FY10: -4.1M FY11: -9.5M FY12: -12.2M FY13: -12.9M FY14: -3M FY15: -13.9M FY16: -47.2M FY17: -10.3M FY18: -14.3M FY19: -24.6M FY20: -20.8M FY21: -17.9M FY22: -47.8M FY23: -59.2M FY24: -29.4M FY25: -51.4M FY26: -69.7M FY02 FY05 FY08 FY11 FY14 FY17 FY20 FY23 FY26

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-75M -50M -25M 0 25M 50M 75M FY11: -841.3K FY12: -3.6M FY13: -3.5M FY14: -2.1M FY15: -2.8M FY16: -4.8M FY17: -7.3M FY18: -9.1M FY19: -14.5M FY20: -15.8M FY21: -12.1M FY22: -45.3M FY23: -49.7M FY24: -25.8M FY25: -42.1M FY26: -66.4M FY12 FY14 FY16 FY18 FY20 FY22 FY24 FY26

Free Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY16: -4.8M FY17: -7.5M FY18: -9.1M FY19: -14.7M FY20: -15.8M FY21: -12.3M FY22: -45.5M FY23: -50.2M FY24: -25.8M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 30M 60M 90M FY11: 5.2M FY12: 14.7M FY13: 18.1M FY14: 1.1M FY15: 1.3M FY16: 1.8M FY21: 86.1M FY22: 6.6M FY23: 7M FY24: 19.4M FY25: 30.9M FY26: 38.1M FY12 FY14 FY16 FY22 FY24 FY26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q4 '11: -1.82 Q1 '12: -1.85 Q2 '12: -1.70 Q3 '12: -1.33 Q4 '12: -0.83 Q1 '13: -0.72 Q2 '13: -0.69 Q3 '13: -1.26 Q4 '13: -1.27 Q1 '14: -1.18 Q2 '14: -2.43 Q3 '15: -4.74 Q4 '15: -7.41 Q1 '16: -26.45 Q2 '16: -29.81 Q3 '16: -30.68 Q4 '16: -30.07 Q1 '17: -11.35 Q2 '17: -6.51 Q3 '17: -4.90 Q4 '17: -1.59 Q1 '18: -1.36 Q2 '18: -1.47 Q3 '18: -1.38 Q4 '18: -1.25 Q1 '19: -1.17 Q2 '19: -0.94 Q3 '19: -0.93 Q4 '19: -0.91 Q1 '20: -0.86 Q2 '20: -0.69 Q3 '20: -0.60 Q4 '20: -0.51 Q1 '21: -0.43 Q2 '21: -0.35 Q3 '21: -0.27 Q4 '21: -0.39 Q1 '22: -0.36 Q2 '22: -0.38 Q3 '22: -0.36 Q4 '22: -2.58 Q1 '23: -5.41 Q2 '23: -7.88 Q3 '23: -9.25 Q4 '23: -8.54 Q1 '24: -6.61 Q2 '24: -4.73 Q3 '24: -3.53 Q4 '24: -2.07 Q1 '25: -1.48 Q2 '25: -1.24 Q3 '25: -1.48 Q4 '25: -1.67 Q1 '26: -1.79 Q2 '26: -1.91 Q3 '26: -1.90 Q4 '26: -1.83 Q1 '27: -1.66 Q1 '12 Q1 '14 Q1 '17 Q1 '19 Q1 '21 Q1 '23 Q1 '25 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.